{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:17Z","timestamp":1793037617175,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012093","name":"Valle de Hebr\u00f3n Instituto de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jhepr.2025.101473","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T02:48:13Z","timestamp":1750474093000},"page":"101473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Navigating liver toxicity in the age of novel oncological agents"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-2052","authenticated-orcid":false,"given":"Mar","family":"Riveiro-Barciela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101473_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","article-title":"Increasing cure rates of solid tumors by immune checkpoint inhibitors","volume":"12","author":"Ma","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib3","series-title":"Committee for medicinal products for human use (CHMP). EMA\/CHMP\/472365\/2024","author":"Agency","year":"2024"},{"key":"10.1016\/j.jhepr.2025.101473_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/liv.15821","article-title":"Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital","volume":"44","author":"Pocurull","year":"2024","journal-title":"Liver Int : official J Int Assoc Study Liver"},{"key":"10.1016\/j.jhepr.2025.101473_bib5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hep.28813","article-title":"Liver injury from herbal and dietary supplements","volume":"65","author":"Navarro","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2025.101473_bib7","article-title":"Challenges in herbal-induced liver injury identification and prevention","volume":"45","author":"Halegoua-DeMarzio","year":"2025","journal-title":"Liver Int : official J Int Assoc Study Liver"},{"key":"10.1016\/j.jhepr.2025.101473_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2025.101473_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101473_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/apt.17898","article-title":"An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury","volume":"59","author":"Riveiro-Barciela","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101473_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001664","article-title":"Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)","volume":"9","author":"Gonzalez-Cao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2025.101473_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.916213","article-title":"The low incidence of viral hepatitis reactivation among subjects on immunotherapy reduces the impact of suboptimal screening rate","volume":"9","author":"Aceituno","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16097","article-title":"Role of liver biopsy in the management of idiosyncratic DILI","volume":"45","author":"Kleiner","year":"2025","journal-title":"Liver Int : official J Int Assoc Study Liver"},{"key":"10.1016\/j.jhepr.2025.101473_bib14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2021.12.043","article-title":"Value of liver biopsy in the diagnosis of drug-induced liver injury","volume":"76","author":"Ahmad","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib15","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2352-3026(19)30201-7","article-title":"Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement","volume":"7","author":"Mahadeo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jhepr.2025.101473_bib16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib17","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol : official J Eur Soc Med Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib18","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol : official J Am Soc Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib19","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.17373","article-title":"Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: an international, multicentre, propensity score-matched analysis","volume":"57","author":"Niu","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101473_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.820724","article-title":"Role of corticosteroids in drug-induced liver injury. A systematic review","volume":"13","author":"Bj\u00f6rnsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101473_bib21","article-title":"CDK4\/6 inhibitor-induced liver injury: clinical phenotypes and role of corticosteroid treatment","volume":"6","author":"Meunier","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101473_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16198","article-title":"Immune-mediated liver injury from checkpoint inhibitor: an evolving frontier with emerging challenges","volume":"45","author":"Dara","year":"2025","journal-title":"Liver Int : official J Int Assoc Study Liver"},{"key":"10.1016\/j.jhepr.2025.101473_bib23","first-page":"162","article-title":"Ursodeoxycholic acid for the management of drug-induced liver injury: role of hepatoprotective and anti-cholestatic mechanisms","volume":"13","author":"Bessone","year":"2025","journal-title":"J Clin translational Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib24","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib25","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","article-title":"Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure","volume":"137","author":"Lee","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101473_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2025.1541020","article-title":"Management of drug-induced liver injury associated with anti-cancer therapy","volume":"16","author":"Vincenzi","year":"2025","journal-title":"Front Physiol"},{"key":"10.1016\/j.jhepr.2025.101473_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2015.08.018","article-title":"High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial","volume":"64","author":"Larsen","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101473_bib30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cgh.2022.03.050","article-title":"Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: results from a prospective multicenter study","volume":"21","author":"Riveiro-Barciela","year":"2023","journal-title":"Clin Gastroenterol Hepatol : official Clin Pract J Am Gastroenterological Assoc"},{"key":"10.1016\/j.jhepr.2025.101473_bib31","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.jhepr.2025.101473_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jhepr.2025.101473_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","article-title":"Immune therapy for cancer","volume":"27","author":"Dougan","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jhepr.2025.101473_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.14216\/kjco.24009","article-title":"The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives","volume":"20","author":"Ahuja","year":"2024","journal-title":"Korean J Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib35","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.jhepr.2025.101473_bib36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/gutjnl-2024-332125","article-title":"Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events","volume":"74","author":"De Martin","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101473_bib37","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int : official J Int Assoc Study Liver"},{"key":"10.1016\/j.jhepr.2025.101473_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1875639","article-title":"A multicenter characterization of hepatitis associated with immune checkpoint inhibitors","volume":"10","author":"Patrinely","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jhepr.2025.101473_bib39","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","article-title":"Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival","volume":"149","author":"Miah","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020302","article-title":"Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma","volume":"14","author":"W\u00f6lffer","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2025.101473_bib41","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101473_bib42","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101473_bib43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhepr.2025.101473_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.gastrohep.2023.10.009","article-title":"Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: position statement of the AEEH-AEG-SEPD-SEOM-GETECCU","volume":"47","author":"Riveiro-Barciela","year":"2024","journal-title":"Gastroenterologia y hepatologia"},{"key":"10.1016\/j.jhepr.2025.101473_bib45","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/apt.18276","article-title":"Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM","volume":"60","author":"Hountondji","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101473_bib46","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s10238-022-00938-6","article-title":"Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis","volume":"23","author":"Tian","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253070","article-title":"Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy","volume":"16","author":"Cunningham","year":"2021","journal-title":"PloS one"},{"issue":"10","key":"10.1016\/j.jhepr.2025.101473_bib48","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.jhepr.2023.100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10- year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101473_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000518","article-title":"Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors","volume":"8","author":"Fontana","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101473_bib50","article-title":"PD-1\/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease","volume":"14","author":"Kocheise","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2025.101473_bib51","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","article-title":"Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients","volume":"15","author":"Biewenga","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2025.101473_bib52","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000528698","article-title":"Adverse events of immune checkpoint inhibitor-based therapies for unresectable hepatocellular carcinoma in prospective clinical trials: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2023","journal-title":"Liver cancer"},{"key":"10.1016\/j.jhepr.2025.101473_bib53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Celsa","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib54","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-related hepatitis with immunotherapy: are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib55","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.32215","article-title":"Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis","volume":"75","author":"Li","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2025.101473_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.928390","article-title":"The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy","volume":"12","author":"Bruera","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib57","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","article-title":"Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies?","volume":"70","author":"Riveiro-Barciela","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102203","article-title":"Acute liver failure following immune checkpoint inhibitors","volume":"47","author":"Renault","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101473_bib59","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib60","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s12072-024-10688-0","article-title":"Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2025.101473_bib61","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2025.101473_bib62","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.bulcan.2020.04.019","article-title":"Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab","volume":"107","author":"Bouhlel","year":"2020","journal-title":"Bull du Cancer"},{"key":"10.1016\/j.jhepr.2025.101473_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241304680","article-title":"Incidence of antibody-drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jhepr.2025.101473_bib64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/oncolo\/oyad308","article-title":"Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study","volume":"29","author":"Botticelli","year":"2024","journal-title":"The oncologist"},{"key":"10.1016\/j.jhepr.2025.101473_bib65","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib66","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J Clin Oncol : official J Am Soc Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib67","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/17512433.2023.2262673","article-title":"The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis","volume":"16","author":"Xu","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101473_bib68","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib69","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jhepr.2025.101473_bib70","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib71","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.5604\/01.3001.0012.7207","article-title":"Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine?","volume":"17","author":"Lepelley","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhepr.2025.101473_bib72","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1159\/000521933","article-title":"Trastuzumab emtansine-induced nodular regenerative hyperplasia: is dose reduction enough as a preventable measure?","volume":"40","author":"Garrido","year":"2022","journal-title":"Dig Dis (Basel, Switzerland)"},{"key":"10.1016\/j.jhepr.2025.101473_bib73","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.220536","article-title":"Noncirrhotic portal hypertension after trastuzumab emtansine in HER2-positive breast cancer as determined by deep learning-measured spleen volume at CT","volume":"305","author":"Choi","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2025.101473_bib74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s13691-019-00392-4","article-title":"Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer","volume":"9","author":"Fujii","year":"2020","journal-title":"Int Cancer Conf J"},{"key":"10.1016\/j.jhepr.2025.101473_bib75","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.jhepr.2025.101473_bib76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhepr.2025.101473_bib77","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1177\/1078155220910252","article-title":"Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: a case report","volume":"26","author":"Hassan","year":"2020","journal-title":"J Oncol Pharm Pract : official Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.jhepr.2025.101473_bib78","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhepr.2025.101473_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jhepr.2025.101473_bib80","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhepr.2025.101473_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20165","article-title":"Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw open"},{"key":"10.1016\/j.jhepr.2025.101473_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061766","article-title":"Hepatotoxicity of small molecule protein kinase inhibitors for cancer","volume":"15","author":"Vigan\u00f2","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2025.101473_bib83","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12876-021-01825-2","article-title":"Zanubrutinib-induced liver injury: a case report and literature review","volume":"21","author":"Atallah","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101473_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101473_bib85","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.28692","article-title":"Vemurafenib-induced granulomatous hepatitis","volume":"65","author":"Spengler","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2025.101473_bib86","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12032-009-9284-y","article-title":"Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors","volume":"27","author":"Tonyali","year":"2010","journal-title":"Med Oncol (Northwood, Lond England)"},{"key":"10.1016\/j.jhepr.2025.101473_bib87","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1200\/JCO.2011.41.0332","article-title":"Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients","volume":"30","author":"Klempner","year":"2012","journal-title":"J Clin Oncol : official J Am Soc Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107789","article-title":"Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: experience with sotorasib in two French anti-cancer centers and practical guidance proposal","volume":"191","author":"Chour","year":"2024","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jhepr.2025.101473_bib89","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/10781552231208390","article-title":"Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer","volume":"30","author":"Sozer Karadagli","year":"2024","journal-title":"J Oncol Pharm Pract : official Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.jhepr.2025.101473_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.876868","article-title":"N-acetylcysteine for the management of non-acetaminophen drug-induced liver injury in adults: a systematic review","volume":"13","author":"Sanabria-Cabrera","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101473_bib91","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/bph.14664","article-title":"Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity","volume":"176","author":"Zhao","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101473_bib92","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/tbj.13532","article-title":"CDK 4\/6 inhibitor successful rechallenge after limiting hepatic toxicity","volume":"26","author":"Meynard","year":"2020","journal-title":"Breast J"},{"key":"10.1016\/j.jhepr.2025.101473_bib93","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/10781552231154009","article-title":"Ribociclib-induced hepatotoxicity","volume":"29","author":"Er","year":"2023","journal-title":"J Oncol Pharm Pract : official Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.jhepr.2025.101473_bib94","first-page":"5211","article-title":"Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity","volume":"34","author":"Yonesaka","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhepr.2025.101473_bib95","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2169\/internalmedicine.51.6285","article-title":"Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity","volume":"51","author":"Kunimasa","year":"2012","journal-title":"Intern Med (Tokyo, Japan)"},{"key":"10.1016\/j.jhepr.2025.101473_bib96","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/OTT.S393165","article-title":"Successful retreatment with crizotinib after crizotinib-induced liver failure in ALK-positive advanced lung adenocarcinoma: a case report","volume":"16","author":"Zhang","year":"2023","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.jhepr.2025.101473_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102718","article-title":"The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers","volume":"125","author":"Starzer","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhepr.2025.101473_bib98","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib99","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.euo.2021.05.007","article-title":"Characterization and management of treatment-emergent hepatic toxicity in patients with advanced renal cell carcinoma receiving first-line pembrolizumab plus axitinib. Results from the KEYNOTE-426 trial","volume":"5","author":"Rini","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib101","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib102","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann Oncol : official J Eur Soc Med Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib103","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib104","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib105","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cncr.23099","article-title":"Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases","volume":"110","author":"Ribero","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2025.101473_bib106","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib107","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101473_bib108","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol : official J Am Soc Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib109","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol : official J Eur Soc Med Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib110","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J Clin Oncol : official J Am Soc Clin Oncol"},{"key":"10.1016\/j.jhepr.2025.101473_bib111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2002-30106","article-title":"Drugs and steatohepatitis","volume":"22","author":"Farrell","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101473_bib112","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"New Engl J Med"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592500151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592500151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:55:02Z","timestamp":1757094902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592500151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":112,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S258955592500151X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101473","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating liver toxicity in the age of novel oncological agents","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101473"}}